
|Articles|December 14, 2022
Readying Biologics for Commercialization
Author(s)Thermo Fisher Scientific
Given the risks and opportunities inherent in drug development, choosing the right late-phase strategy to optimize timelines and capacity, while remaining flexible enough for changing market conditions, presents a significant challenge to companies developing and commercializing biopharmaceutical products. This piece highlights new technologies and strategies to reduce risk and execute consistently.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
5